This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
A 63-year-old woman developed severe hyponatremia (sodium 122 mmol/L) and seizures from SIADH just 4 days after starting tirzepatide for weight loss. She had no prior medical history. Stopping tirzepatide and fluid restriction resolved the condition.
Why it matters
SIADH causing seizures is a potentially life-threatening complication not widely recognized with GLP-1 drugs. This case warns clinicians to monitor electrolytes when starting tirzepatide, even in low-risk patients.
The numbers in context
63-year-old woman. No past medical history. Tonic-clonic seizures 4 days after starting tirzepatide. Serum sodium 122 mmol/L. Low serum osmolality. High urine osmolality and urine sodium consistent with SIADH. Full recovery after discontinuation and fluid restriction.
How the study worked
Single case report with clinical documentation, laboratory workup confirming SIADH, exclusion of other causes, and follow-up after drug discontinuation.
Who was studied
63-year-old woman using tirzepatide off-label for weight loss
What this study cannot tell us
Single case. Cannot determine incidence of this complication. No rechallenge performed. Other unrecognized causes cannot be completely excluded.
Read the original research
Tirzepatide-Induced Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Presenting With Seizures.
JCEM case reports, 3(12), luaf261
Citation
Shah, Islam; Sennik, Devesh; Veettil, Fahas Ali Vattiyam. (2025). Tirzepatide-Induced Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Presenting With Seizures.. JCEM case reports, 3(12), luaf261. https://doi.org/10.1210/jcemcr/luaf261